, GlobeNewswire
Addex to Present at The New York Academy of Sciences
Addex Pharmaceuticals / Addex to Present at The New York Academy of Sciences verarbeitet und übermittelt durch Hugin. Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Data on Promising Clinical-Stage Parkinson's Disease Product
Addex Discovery Capabilities Illustrated
Geneva, Switzerland, 17 February 2010 - Addex Pharmaceuticals (SIX:ADXN), the
allosteric modulation company, announced today that it will participate at an
event hosted by The New York Academy of Sciences entitled, "Metabotropic
Glutamate Receptors: Translation from Discovery to Clinical Trials." Dr.
Jean-Philippe Rocher, head of core chemistry at Addex, will discuss the
discovery and development of ADX48621 in a talk entitled: "Discovery of a Novel
Series of Selective mGluR5 Negative Allosteric Modulators." ADX48621 has
completed Phase I clinical development and is scheduled to start Phase II
testing in the fourth quarter of 2010.
Metabotropic glutamate receptors were first described in 1987 and cloned in the
early '90s. Today they are considered the single most promising new collection
of targets for CNS drug discovery, with therapeutic potential to treat illnesses
ranging from migraine to esophageal reflux, and from schizophrenia to
Parkinson's disease.
The symposium, to be held at the New York Academy of Sciences conference center
in New York City on February 23, 2010, from 1:00 pm - 5:00 pm, brings together
national and international experts from academia and industry to present
research spanning intramolecular signal transduction, regulation, pharmacology,
their role in motor function, and the therapeutic use.
For more information about the event please visit:
http://www.nyas.org/metabotropic
The New York Academy of Sciences is an independent, not-for-profit organization
committed to advancing science, technology, and society worldwide since 1817.
With 24,000 members in 140 countries, NYAS is creating a global community of
science for the benefit of humanity. NYAS' core mission is to advance scientific
knowledge, positively impact the major global challenges of society with
science-based solutions, and increase the number of scientifically informed
individuals in society at large.
Investors and media interested to attend please contact:
Adrienne Burke
Director, Public Outreach
The New York Academy of Science
250 Greenwich St., 40th floor
New York, NY 10007
+1 (212) 298-8655
aburke@nyas.org
Addex Pharmaceuticals (www.addexpharma.com
utilizes its unique proprietary platform technologies to discover and develop
allosteric modulators for human health. Allosteric modulators are a different
kind of orally available small molecule therapeutic agent, which we believe will
offer a competitive advantage over classical drugs. With 15 programs in
development, the Addex pipeline demonstrates the productivity and broad
potential of our unparalleled platform technologies. The most advanced product,
ADX48621, an mGluR5 negative allosteric modulator (NAM), has completed Phase I
testing and is scheduled to start Phase II testing for Parkinson's disease
levodopa associated dyskinesia (PD-LID) later this year.
Our products and technology already have proven their value through our
relationships with four of the top10 pharmaceutical companies in the world.
Specifically, under an agreement with Ortho-McNeil-Janssen Inc., a Johnson &
Johnson company, ADX71149, an mGluR2 positive allosteric modulator (PAM), is
undergoing Phase I clinical testing and has potential for treatment of
schizophrenia and anxiety. Under two separate agreements with Merck & Co., Inc.,
we are developing PAMs of mGluR4 and mGluR5 as drugs to treat Parkinson's
disease and schizophrenia, respectively. In addition, SR-One, the corporate
venture arm of GlaxoSmithKline, and Roche Venture Fund have made equity
investments in Addex.
Chris Maggos
Investor Relations & Communications
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos@addexpharma.com
Disclaimer: The foregoing release contains forward-looking statements that can
be identified by terminology such as "not approvable", "continue", "believes",
"believe", "will", "remained open to exploring", "would", "could", or similar
expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, and involve known and unknown
risks, uncertainties and other factors that may cause actual results with
allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets to
be materially different from any future results, performance or achievements
expressed or implied by such statements. There can be no guarantee that
allosteric modulators of mGluR4, mGluR2 or mGluR5 will be approved for sale in
any market or by any regulatory authority. Nor can there be any guarantee
that allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic
targets will achieve any particular levels of revenue (if any) in the future. In
particular, management's expectations regarding allosteric modulators of
mGluR4, mGluR2, mGluR5 or other therapeutic targets could be affected by, among
other things, unexpected actions by our partners, unexpected regulatory actions
or delays or government regulation generally; unexpected clinical trial results,
including unexpected new clinical data and unexpected additional analysis of
existing clinical data; competition in general; government, industry and general
public pricing pressures; the company's ability to obtain or maintain patent or
other proprietary intellectual property protection. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated, believed,
estimated or expected. Addex Pharmaceuticals is providing the information in
this press release as of this date and does not undertake any obligation to
update any forward-looking statements contained in this press release as a
result of new information, future events or otherwise.
[HUG#1385509]
--- Ende der Mitteilung ---
Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Schweiz
ISIN: CH0029850754;
Data on Promising Clinical-Stage Parkinson's Disease Product
Addex Discovery Capabilities Illustrated
Geneva, Switzerland, 17 February 2010 - Addex Pharmaceuticals (SIX:ADXN), the
allosteric modulation company, announced today that it will participate at an
event hosted by The New York Academy of Sciences entitled, "Metabotropic
Glutamate Receptors: Translation from Discovery to Clinical Trials." Dr.
Jean-Philippe Rocher, head of core chemistry at Addex, will discuss the
discovery and development of ADX48621 in a talk entitled: "Discovery of a Novel
Series of Selective mGluR5 Negative Allosteric Modulators." ADX48621 has
completed Phase I clinical development and is scheduled to start Phase II
testing in the fourth quarter of 2010.
Metabotropic glutamate receptors were first described in 1987 and cloned in the
early '90s. Today they are considered the single most promising new collection
of targets for CNS drug discovery, with therapeutic potential to treat illnesses
ranging from migraine to esophageal reflux, and from schizophrenia to
Parkinson's disease.
The symposium, to be held at the New York Academy of Sciences conference center
in New York City on February 23, 2010, from 1:00 pm - 5:00 pm, brings together
national and international experts from academia and industry to present
research spanning intramolecular signal transduction, regulation, pharmacology,
their role in motor function, and the therapeutic use.
For more information about the event please visit:
http://www.nyas.org/metabotropic
The New York Academy of Sciences is an independent, not-for-profit organization
committed to advancing science, technology, and society worldwide since 1817.
With 24,000 members in 140 countries, NYAS is creating a global community of
science for the benefit of humanity. NYAS' core mission is to advance scientific
knowledge, positively impact the major global challenges of society with
science-based solutions, and increase the number of scientifically informed
individuals in society at large.
Investors and media interested to attend please contact:
Adrienne Burke
Director, Public Outreach
The New York Academy of Science
250 Greenwich St., 40th floor
New York, NY 10007
+1 (212) 298-8655
aburke@nyas.org
Addex Pharmaceuticals (www.addexpharma.com
utilizes its unique proprietary platform technologies to discover and develop
allosteric modulators for human health. Allosteric modulators are a different
kind of orally available small molecule therapeutic agent, which we believe will
offer a competitive advantage over classical drugs. With 15 programs in
development, the Addex pipeline demonstrates the productivity and broad
potential of our unparalleled platform technologies. The most advanced product,
ADX48621, an mGluR5 negative allosteric modulator (NAM), has completed Phase I
testing and is scheduled to start Phase II testing for Parkinson's disease
levodopa associated dyskinesia (PD-LID) later this year.
Our products and technology already have proven their value through our
relationships with four of the top10 pharmaceutical companies in the world.
Specifically, under an agreement with Ortho-McNeil-Janssen Inc., a Johnson &
Johnson company, ADX71149, an mGluR2 positive allosteric modulator (PAM), is
undergoing Phase I clinical testing and has potential for treatment of
schizophrenia and anxiety. Under two separate agreements with Merck & Co., Inc.,
we are developing PAMs of mGluR4 and mGluR5 as drugs to treat Parkinson's
disease and schizophrenia, respectively. In addition, SR-One, the corporate
venture arm of GlaxoSmithKline, and Roche Venture Fund have made equity
investments in Addex.
Chris Maggos
Investor Relations & Communications
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos@addexpharma.com
Disclaimer: The foregoing release contains forward-looking statements that can
be identified by terminology such as "not approvable", "continue", "believes",
"believe", "will", "remained open to exploring", "would", "could", or similar
expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, and involve known and unknown
risks, uncertainties and other factors that may cause actual results with
allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets to
be materially different from any future results, performance or achievements
expressed or implied by such statements. There can be no guarantee that
allosteric modulators of mGluR4, mGluR2 or mGluR5 will be approved for sale in
any market or by any regulatory authority. Nor can there be any guarantee
that allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic
targets will achieve any particular levels of revenue (if any) in the future. In
particular, management's expectations regarding allosteric modulators of
mGluR4, mGluR2, mGluR5 or other therapeutic targets could be affected by, among
other things, unexpected actions by our partners, unexpected regulatory actions
or delays or government regulation generally; unexpected clinical trial results,
including unexpected new clinical data and unexpected additional analysis of
existing clinical data; competition in general; government, industry and general
public pricing pressures; the company's ability to obtain or maintain patent or
other proprietary intellectual property protection. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated, believed,
estimated or expected. Addex Pharmaceuticals is providing the information in
this press release as of this date and does not undertake any obligation to
update any forward-looking statements contained in this press release as a
result of new information, future events or otherwise.
[HUG#1385509]
--- Ende der Mitteilung ---
Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Schweiz
ISIN: CH0029850754;
Relevante Links: Addex Therapeutics Ltd